evidence/gaps
Cochrane · systematic review · CD001990

Chemotherapy versus best supportive care for extensive small cell lung cancer

Pelayo Alvarez, M, Westeel, V, Cortés‐Jofré, M, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library

Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 33.3%Low 2 · 33.3%Moderate 2 · 33.3%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

First‐line chemotherapy compared with BSC for extensive SCLC

Population: patients with extensive SCLC without previous treatment
2 questions
OutcomeEffectEvidenceStatus / GRADE
Overall survival
First‐line chemotherapy vs BSC
no estimate extracted2 studies · 65 participantsVery low
Downgraded: risk of bias, imprecision
Adverse effects
First‐line chemotherapy vs BSC
no estimate extracted2 studies · 65 participantsVery low
Downgraded: risk of bias, imprecision

Second‐line chemotherapy at relapse or progression in extensive SCLC

Population: patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
4 questions
OutcomeEffectEvidenceStatus / GRADE
Overall survival
HR 0.73 [0.55, 0.96]2 studies · 542 participantsLow
Downgraded: risk of bias, imprecision
Toxic death
no estimate extracted2 studies · 542 participantsModerate
Downgraded: risk of bias, imprecision
Adverse effects
no estimate extracted2 studies · 542 participantsModerate
Downgraded: risk of bias, imprecision
Quality of life
RR 2.18 [0.05, 0.25]1 study · 141 participantsLow
Downgraded: risk of bias, imprecision